News

Under the deal, the two parties will collaborate on an NIH-sponsored Phase II trial of AV-101, VistaGen’s orally-active NMDA receptor modulator, in MDD patients. MDD is a debilitating

The injection is indicated for prophylaxis of deep vein thrombosis (DVT) in patients undergoing abdominal surgery, hip or knee replacement surgery, or in medical patients with severely restricted

The company is developing GLPG1690 in collaboration with Janssen Pharmaceutica. Around 40 healthy volunteers were included in the trial, which evaluated the safety, tolerability, pharmacokinetics and pharmacodynamics of

The launch of three drug discovery institutes at the University of Cambridge, University of Oxford and University College London (UCL) will see 90 new research scientists recruited over

Banzel is a triazole derivative, which is structurally unrelated to currently marketed antiepileptic drugs. Earlier, the FDA had approved Banzel as adjunctive treatment of seizures associated with LGS

Inflectra is a chimeric human murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNF alpha but not to lymphotoxin a (TNF

BXQ-350 is a nanovesicle formulation of Saposin C (sphingolipid activator protein C) and the phospholipid dioleoylphosphatidylserine (DOPS). Earlier, the company secured a Phase II Bridge Award (Small Business

The company has reported that ONS-3010 met the primary endpoints in its first-in-human study, which was conducted by the Centre for Human Drug Research (CHDR) in Leiden, The

ZYAN1 is an orally bioavailable hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitor being developed to increase the natural production of erythropoietin (EPO) as well as the efficacy of injectable EPO